Lisata Therapeutics
LSTA
23 hedge funds and large institutions have $1.83M invested in Lisata Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0.03% less ownership
Funds ownership: 0.45% → 0.43% (-0.03%)
8% less funds holding
Funds holding: 25 → 23 (-2)
23% less capital invested
Capital invested by funds: $2.39M → $1.83M (-$560K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$59.9K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$28.7K |
| 3 |
Renaissance Technologies
New York
|
+$8.92K |
| 4 |
Morgan Stanley
New York
|
+$121 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$61 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$51K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$37.2K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$14.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.04K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
-$3.22K |
LSTA Hedge Fund Activity: Q3 2017 in Review
23 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2017, worth a combined $1.83M — down 23% from $2.39M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSTA and 2 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $59.9K. The largest seller was Ameriprise, exiting entirely with an estimated $51K sold.
- 23 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2017, down from 25 in Q2 2017.
- Funds reported $1.83M of Lisata Therapeutics stock for Q3 2017, down 23% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q3 2017 and 4 closed out, a net change of -2 holders.
- The largest Lisata Therapeutics buyer in Q3 2017 was Jacobs Levy Equity Management, an estimated $59.9K added.
- The largest Lisata Therapeutics seller in Q3 2017 was Ameriprise, an estimated $51K sold.
Based on aggregated 13F filings for Q3 2017.